Ultragenyx Pharmaceutical (RARE) Exchange Rate Effect (2017 - 2026)
Ultragenyx Pharmaceutical's (RARE) quarterly Exchange Rate Effect came in at -$1.0 million in Q1 2026, down 200.0% year-on-year from $1.0 million in Q1 2025, and down 52.44% on a QoQ basis from -$656000.0 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Exchange Rate Effect (2017 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 10 years of Exchange Rate Effect data on file, last reported at -$1.0 million in Q1 2026.
- On a quarterly basis, Exchange Rate Effect fell 200.0% year-over-year to -$1.0 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a 723.05% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 300.0% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at -$1.0 million, down from -$656000.0 in the prior quarter.
- Over the last five years, Exchange Rate Effect for RARE reached as high as $3.4 million in Q2 2025 and fell as low as -$1.9 million in Q4 2024.
- Historically, Exchange Rate Effect has averaged -$4411.8 across 5 years, with a median of -$136000.0 in 2023.
- Across the five-year window, Exchange Rate Effect sank 421.8% in 2024 and jumped 618.83% in 2025, its largest moves.
- Year by year, Exchange Rate Effect stood at $1.4 million in 2022, then plunged by 52.59% to $641000.0 in 2023, then plunged by 403.9% to -$1.9 million in 2024, then jumped by 66.32% to -$656000.0 in 2025, then sank by 52.44% to -$1.0 million in 2026.
- Per Business Quant data, the three most recent Exchange Rate Effect figures were -$1.0 million in Q1 2026, -$656000.0 in Q4 2025, and $294000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 619,347.27 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 19.32 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 14,631.83 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -40.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -900,000.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.72 Bn | 2.31 Bn | 106.00 Mn | -1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.00 Mn |
| Mar 31, 2026 | -1.00 Mn |
| Dec 31, 2025 | -656,000.00 |
| Dec 31, 2025 | -656,000.00 |
| Sep 30, 2025 | 294,000.00 |
| Sep 30, 2025 | 294,000.00 |
| Jun 30, 2025 | 3.36 Mn |
| Jun 30, 2025 | 3.36 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | -648,000.00 |
| Jun 30, 2024 | -648,000.00 |
| Mar 31, 2024 | -679,000.00 |
| Mar 31, 2024 | -679,000.00 |
| Dec 31, 2023 | 641,000.00 |
| Dec 31, 2023 | 641,000.00 |